Bispecific antibodies for viral immunotherapy.

Abstract

Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies. While the bispecific antibody approach has been applied widely to targets for indications such as cancer and inflammation, the development of such agents for viral immunotherapy is only now emerging. Here, we review recent advances in the development of bispecific antibodies for viral immunotherapy, highlighting promising in vitro and in vivo results.

• Authors: Elisabeth K Nyakatura, Alexandra Y Soare, Jonathan R Lai
• Journal: Human vaccines & immunotherapeutics (Hum Vaccin Immunother) Vol. 13 Issue 4 Pg. 836-842 (04 03 2017) ISSN: 2164-554X [Electronic] United States
• PMID: 27786606 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)

Chemical References

• Antibodies, Bispecific
• Antibodies, Monoclonal
• Antibodies, Viral
• Immunologic Factors

Topics

• Animals
• Antibodies, Bispecific (administration & dosage, immunology)
• Antibodies, Monoclonal (administration & dosage, immunology)
• Antibodies, Viral (administration & dosage, immunology)
• Drug Discovery (trends)
• Humans
• Immunologic Factors (administration & dosage, immunology)
• Immunotherapy (methods)
• Mice
• Virus Diseases (therapy)